Department of Intensive Care Medicine, HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo, 315000, Zhejiang, China.
Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, 315000, Zhejiang, China.
BMC Pulm Med. 2022 Apr 1;22(1):121. doi: 10.1186/s12890-022-01914-2.
The respiratory rate-oxygenation (ROX) index has been increasingly applied to predict the outcome of high-flow nasal cannula (HFNC) in pneumonia patients with acute hypoxemic respiratory failure (AHRF). However, its diagnostic accuracy for the HFNC outcome has not yet been systematically assessed. This meta-analysis sought to evaluate the predictive performance of the ROC index for the successful weaning from HFNC in pneumonia patients with AHRF.
A literature search was conducted on electronic databases through February 12, 2022, to retrieve studies that investigated the diagnostic accuracy of the ROC index for the outcome of HFNC application in pneumonia patients with AHRF. The area under the hierarchical summary receiver operating characteristic curve (AUHSROC) was estimated as the primary measure of diagnostic accuracy due to the varied cutoff values of the index. We observed the distribution of the cutoff values and estimated the optimal threshold with corresponding 95% confidential interval (CI).
Thirteen observational studies comprising 1751 patients were included, of whom 1003 (57.3%) successfully weaned from HFNC. The ROC index exhibits good performance for predicting the successful weaning from HFNC in pneumonia patients with AHRF, with an AUHSROC of 0.81 (95% CI 0.77-0.84), a pooled sensitivity of 0.71 (95% CI 0.64-0.78), and a pooled specificity of 0.78 (95% CI 0.70-0.84). The cutoff values of the ROX index were nearly conically symmetrically distributed; most data were centered between 4.5 and 6.0, and the mean and median values were 4.8 (95% CI 4.2-5.4) and 5.3 (95% CI 4.2-5.5), respectively. Moreover, the AUHSROC in the subgroup of measurement within 6 h after commencing HFNC was comparable to that in the subgroup of measurement during 6-12 h. The stratified analyses also suggested that the ROC index was a reliable predictor of HFNC success in pneumonia patients with coronavirus disease 2019.
In pneumonia patients with AHRF, the ROX index measured within 12 h after HFNC initiation is a good predictor of successful weaning from HFNC. The range of 4.2-5.4 may represent the optimal confidence interval for the prediction of HFNC outcome.
呼吸频率-氧合(ROX)指数已被越来越多地应用于预测肺炎合并急性低氧性呼吸衰竭(AHRF)患者高流量鼻导管(HFNC)治疗的结局。然而,其对 HFNC 结局的诊断准确性尚未得到系统评估。本荟萃分析旨在评估 ROX 指数预测肺炎合并 AHRF 患者 HFNC 撤机成功的预测性能。
通过电子数据库检索截至 2022 年 2 月 12 日的文献,以评估 ROX 指数对肺炎合并 AHRF 患者 HFNC 应用结局的诊断准确性。由于指数的截断值不同,采用分层汇总受试者工作特征曲线下面积(AUHSROC)作为主要的诊断准确性测量指标。我们观察了截断值的分布,并估计了最佳阈值及其相应的 95%置信区间(CI)。
共纳入了 13 项包含 1751 例患者的观察性研究,其中 1003 例(57.3%)成功撤机。ROX 指数对预测肺炎合并 AHRF 患者 HFNC 撤机成功具有良好的性能,AUHSROC 为 0.81(95%CI 0.77-0.84),合并敏感度为 0.71(95%CI 0.64-0.78),合并特异度为 0.78(95%CI 0.70-0.84)。ROX 指数的截断值呈近乎锥形对称分布;大多数数据集中在 4.5 到 6.0 之间,均值和中位数分别为 4.8(95%CI 4.2-5.4)和 5.3(95%CI 4.2-5.5)。此外,HFNC 开始后 6 小时内测量的 AUHSROC 与 HFNC 开始后 6-12 小时内测量的 AUHSROC 相当。分层分析还表明,ROX 指数是预测肺炎合并 2019 冠状病毒病患者 HFNC 成功的可靠指标。
在肺炎合并 AHRF 患者中,HFNC 开始后 12 小时内测量的 ROX 指数是 HFNC 撤机成功的良好预测指标。4.2-5.4 可能代表 HFNC 结局预测的最佳置信区间。